227 related articles for article (PubMed ID: 33414264)
1. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
2. Chronic immune checkpoint inhibitor pneumonitis.
Naidoo J; Cottrell TR; Lipson EJ; Forde PM; Illei PB; Yarmus LB; Voong KR; Feller-Kopman D; Lee H; Riemer J; Wang D; Taube JM; Brahmer JR; Lin CT; Danoff SK; D'Alessio FR; Suresh K
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554618
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
6. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350
[TBL] [Abstract][Full Text] [Related]
7. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
8. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
Balaji A; Verde F; Suresh K; Naidoo J
Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
[TBL] [Abstract][Full Text] [Related]
9. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
[TBL] [Abstract][Full Text] [Related]
10. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review.
Lai KC; Hsiao YH; Chen SC
Front Immunol; 2022; 13():994064. PubMed ID: 36119082
[TBL] [Abstract][Full Text] [Related]
11. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
[TBL] [Abstract][Full Text] [Related]
12. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
Sawai Y; Katsuya Y; Shinozaki-Ushiku A; Iwasaki A; Fukayama M; Watanabe K; Nagase T
Drug Discov Ther; 2019 Jul; 13(3):164-167. PubMed ID: 31257354
[TBL] [Abstract][Full Text] [Related]
13. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
15. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
[TBL] [Abstract][Full Text] [Related]
16. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
17. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
18. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
[TBL] [Abstract][Full Text] [Related]
19. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes.
Banavasi H; Kim S; Alkassis S; Daoud A; Laktineh A; Nagasaka M; Sukari A; Soubani AO
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):144-150. PubMed ID: 34688626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
